Price Alert

Standard BioTools Inc. (LAB)

NASDAQ: LAB · Real-Time Price · USD

1.34

0.06 (4.69%)

At close: Oct 03, 2025, 3:59 PM

1.34

0.00%

After-hours: Oct 03, 2025, 06:39 PM EDT

Standard BioTools Statistics

Share Statistics

Standard BioTools has 382M shares outstanding. The number of shares has increased by 2.62% in one year.

Shares Outstanding	382M
Shares Change (YoY)	2.62%
Shares Change (QoQ)	0.57%
Owned by Institutions (%)	73.97%
Shares Floating	365.52M
Failed to Deliver (FTD) Shares	1,288
FTD / Avg. Volume	0.1%

Short Selling Information

The latest short interest is 11.99M, so 3.14% of the outstanding shares have been sold short.

Short Interest	11.99M
Short % of Shares Out	3.14%
Short % of Float	4.92%
Short Ratio (days to cover)	9.98

Valuation Ratios

The PE ratio is -4.45 and the forward PE ratio is -8.53. Standard BioTools's PEG ratio is 0.1.

PE Ratio	-4.45
Forward PE	-8.53
PS Ratio	3.54
Forward PS	6.4
PB Ratio	1.31
P/FCF Ratio	-4.07
PEG Ratio	0.1

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Standard BioTools.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.7, with a Debt / Equity ratio of 0.07.

Current Ratio	5.7
Quick Ratio	5.09
Debt / Equity	0.07
Debt / EBITDA	-0.28
Debt / FCF	-0.22
Interest Coverage	-52.85

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$214.29K
Profits Per Employee	$-170.62K
Employee Count	814
Asset Turnover	0.28
Inventory Turnover	2.21

Taxes

Income Tax	573K
Effective Tax Rate	-0.41%

Stock Price Statistics

The stock price has increased by -27.57% in the last 52 weeks. The beta is 1.31, so Standard BioTools's price volatility has been higher than the market average.

Beta	1.31
52-Week Price Change	-27.57%
50-Day Moving Average	1.31
200-Day Moving Average	1.31
Relative Strength Index (RSI)	53.37
Average Volume (20 Days)	1,335,490

Income Statement

In the last 12 months, Standard BioTools had revenue of 174.43M and earned -138.88M in profits. Earnings per share was -0.52.

Revenue	174.43M
Gross Profit	84.26M
Operating Income	-175.24M
Net Income	-138.88M
EBITDA	-118.14M
EBIT	-135M
Earnings Per Share (EPS)	-0.52

Full Income Statement

Balance Sheet

The company has 166.73M in cash and 33M in debt, giving a net cash position of 133.73M.

Cash & Cash Equivalents	166.73M
Total Debt	33M
Net Cash	133.73M
Retained Earnings	-1.19B
Total Assets	556.97M
Working Capital	408.01M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -143.45M and capital expenditures -8.36M, giving a free cash flow of -151.81M.

Operating Cash Flow	-143.45M
Capital Expenditures	-8.36M
Free Cash Flow	-151.81M
FCF Per Share	-0.43

Full Cash Flow Statement

Margins

Gross margin is 48.31%, with operating and profit margins of -100.46% and -79.62%.

Gross Margin	48.31%
Operating Margin	-100.46%
Pretax Margin	-79.29%
Profit Margin	-79.62%
EBITDA Margin	-67.73%
EBIT Margin	-100.46%
FCF Margin	-87.03%

Dividends & Yields

LAB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for LAB is $2.5, which is 86.6% higher than the current price. The consensus rating is "Hold".

Price Target	$2.5
Price Target Difference	86.6%
Analyst Consensus	Hold
Analyst Count	2

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	2.96
Piotroski F-Score	2